Beta Bionics Announces Participation in Upcoming Investor Conferences
Beta Bionics, Inc. management will participate in several healthcare-focused investor conferences throughout November and December 2026.
Stocks · News reference
Truist Securities Maintains Buy on Beta Bionics, Raises Price Target to $28
Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $23 to $28.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Kaplan Fox Alerts Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to an Upcoming Deadline of November 3, 2026 in the Securities Class Action
A securities class action lawsuit has been filed against Beta Bionics, Inc. for investors who purchased stock between July 30, 2025 and February 24, 2026. The complaint alleges the company received thousands of complaints about serious, life-threatening hypoglycemia incidents caused by device malfunctions in its iLet insulin pump, which were not properly disclosed. The FDA issued a warning letter on February 24, 2026 detailing violations and contradicting the company's prior statements about the severity of patient incidents. The deadline to move the court to become lead plaintiff is November 3, 2026.
Beta Bionics Reports Third Quarter 2026 Financial Results and Updates Guidance
Beta Bionics reported Q3 2026 net sales of $35.5 million and updated its full-year 2026 revenue guidance to $124 million–$126 million. The company also announced the withdrawal of its 510(k) application for the 3D Intelligence algorithm to provide additional validation data.
Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
A class action securities lawsuit has been filed against Beta Bionics, Inc. for allegedly making false statements about its iLet Bionic Pancreas insulin pump. The lawsuit claims the device's automated dosing algorithm malfunctioned, delivering dangerously high insulin levels and causing hundreds of life-threatening hypoglycemic events. The company allegedly failed to disclose thousands of customer complaints to the FDA and misrepresented the scope of FDA Form 483 findings. Investors who purchased stock between July 30, 2025 and February 24, 2026 can join the lawsuit with a November 3, 2026 deadline to request lead plaintiff status.
8-K filing — Beta Bionics, Inc. (BBNX)
Filed: 2026-10-27 AccNo: 0001171843-26-006856 Size: 356 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Jefferies Initiates Coverage On Beta Bionics with Buy Rating, Announces Price Target of $30
Jefferies analyst Michael Toomey initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Buy rating and announces Price Target of $30.